News
IBIO
1.700
-1.73%
-0.030
Savara COO Robert Lutz to take CFO role as Lowrance steps down for health reasons
PUBT · 1d ago
iBio Price Target Announced at $5.00/Share by Raymond James
Dow Jones · 1d ago
Raymond James Initiates Coverage On iBio with Outperform Rating, Announces Price Target of $5
Benzinga · 1d ago
IBIO INC <IBIO.O>: RAYMOND JAMES INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $5
Reuters · 1d ago
iBio initiated with an Outperform at Raymond James
TipRanks · 1d ago
Weekly Report: what happened at IBIO last week (0601-0605)?
Weekly Report · 1d ago
U.S. RESEARCH ROUNDUP- Adobe, Allstate, Teleflex
Reuters · 1d ago
IBIO INC <IBIO.O>: B. RILEY INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $6
Reuters · 4d ago
U.S. RESEARCH ROUNDUP-Chipotle Mexican Grill, Honeywell, Tesla
Reuters · 4d ago
iBio executives present at Jefferies Global Healthcare Conference
PUBT · 06/02 20:02
iBio doses first participant in IBIO-600 trial
TipRanks · 06/02 11:44
iBio Begins Human Testing of Obesity Drug Candidate, First Patient Dosed in Company's Initial Clinical Trial
Benzinga · 06/02 11:04
iBio doses first patient in Phase 1 trial of obesity drug candidate IBIO-600
PUBT · 06/02 11:04
IBIO BECOMES A CLINICAL-STAGE COMPANY WITH FIRST PARTICIPANT DOSED IN PHASE 1 CLINICAL TRIAL OF IBIO-600 IN ADULTS WITH OBESITY
Reuters · 06/02 11:00
Weekly Report: what happened at IBIO last week (0525-0529)?
Weekly Report · 06/01 09:59
IBIO-600 First-in-Human Obesity Trial Puts iBio on Investors’ Radar
TipRanks · 05/29 16:35
Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit
Seeking Alpha · 05/26 07:56
Weekly Report: what happened at IBIO last week (0518-0522)?
Weekly Report · 05/25 10:02
Weekly Report: what happened at IBIO last week (0511-0515)?
Weekly Report · 05/18 10:02
LifeSci Capital Remains a Buy on Ibio (IBIO)
TipRanks · 05/16 14:36
More
Webull provides a variety of real-time IBIO stock news. You can receive the latest news about Ibio through multiple platforms. This information may help you make smarter investment decisions.
About IBIO
iBio, Inc. is a biotech company leveraging artificial intelligence and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with drug discovery platforms, it is creating a pipeline of antibody treatments to address significant unmet medical needs. Its proprietary StableHu technology is instrumental in this optimization process. StableHu is an AI- powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. It has a pipeline of pre-clinical programs with differentiated profiles and high potential impact, including IBIO-101, its second-generation anti-CD25 monoclonal antibody, a TROP-2 x CD3 bispecific antibody, an antibody that binds to a non-shed, non-glycosylated region of MUC16, an antibody that binds to an epitope on EGFRvIII without binding wildtype EGFR, and an anti-CCR8 antibody.